Indian drugmakers seized on the patent expiry for Novo Nordisk A/S’s blockbuster weight-loss and diabetes medication to roll out cut-price generic versions in a nation with the third-largest overweight population.
Natco Pharma Ltd. plans to make an injection for semaglutide — the active ingredient in both Ozempic and Wegovy — at one of the lowest starting prices of 1,290 rupees ($14) a month. Its pen device is expected to launch by April and cost about 4,500 rupees a month, it said in a filing.
